newsfilter
← Latest News
Business Wire·

bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

  • bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) announced President & CEO Maria Zannes will present a corporate update at the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026.
  • The presentation will cover strategic milestones, commercial momentum for the CyPath® Lung diagnostic test, & advancements in the company's proprietary technology platform.
  • Institutional investors can register for the virtual or in-person event at the Lotte New York Palace Hotel & may request one-on-one meetings via the conference website.
  • A live & archived webcast of the presentation is scheduled for release on September 11, 2026, at https://bit.ly/BIAFPresentation.
  • CyPath® Lung is a noninvasive Laboratory Developed Test (LDT) marketed by Precision Pathology Laboratory Services, a bioAffinity subsidiary, & operates under CLIA regulations administered by the Centers for Medicare & Medicaid Services.
  • The release includes standard forward-looking statements cautioning that actual results may differ from expectations due to risks such as limited operating history, capital needs, competition, & regulatory approval uncertainties.
  • The information in the press release is current as of September 3, 2026.